17874-76-9

Usage

Uses

Used in Pharmaceutical Industry:
2-METHYL HYDROGEN PYRIDINE-2,5-DICARBOXYLATE is used as a building block for the synthesis of various drugs and pharmaceutical intermediates due to its versatile chemical properties and reactivity.
Used as a Chelating Agent:
2-METHYL HYDROGEN PYRIDINE-2,5-DICARBOXYLATE is used as an effective chelating agent for metal ions, which can be beneficial in various pharmaceutical applications, such as stabilizing metal-containing drugs or in the development of metal-based therapies.
Used as an Inhibitor of Metallopeptidases:
2-METHYL HYDROGEN PYRIDINE-2,5-DICARBOXYLATE is used as an inhibitor of metallopeptidases, which are enzymes that play a crucial role in various biological processes. Its ability to inhibit these enzymes can be utilized in the development of drugs targeting specific diseases or conditions where metallopeptidase activity is implicated.

InChI:InChI=1/C8H7NO4/c1-13-8(12)6-3-2-5(4-9-6)7(10)11/h2-4H,1H3,(H,10,11)

Upstream product

• 67-56-1 methanol 
• 100-26-5 Pyridine-2,5-dicarboxylic acid 
• 7664-93-9 sulfuric acid 
• 485-80-3 S-adenosyl-L-methionine 

Downstream Products

• 138834-65-8 methyl 5-[((phenylsulfonyl)amino)carbonyl]-pyridine-2-carboxylate 
• 138834-71-6 methyl 5-[((4-methoxyphenylsulfonyl)amino)carbonyl]-pyridine-2-carboxylate 
• 138834-66-9 methyl 5-[((benzylsulfonyl)amino)carbonyl]-pyridine-2-carboxylate 
• 138834-72-7 5-[4-(4,7-Dichloro-quinolin-2-yl)-benzenesulfonylaminocarbonyl]-pyridine-2-carboxylic acid methyl ester 
• 131052-40-9 methyl 5-[N-(tert-butoxycarbonyl)amino]-pyridine-2-carboxylate 
• 1053735-50-4 5-(4-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]-benzoylamino}-4-methoxycarbonyl-butylcarbamoyl)-pyridine-2-carboxylic acid methyl ester 
• 944456-47-7 methyl 5-((ethylphenylalanine)oxycarbonyl)-2-pyridinecarboxylate 
• 138834-76-1 5-Phenylmethanesulfonylaminocarbonyl-pyridine-2-carboxylic acid 
• 138834-75-0 5-[((phenylsulfonyl)amino)carbonyl]-pyridine-2-carboxylate 
• 873651-92-4 (5-aminopyridin-2-yl)methanol 
• 323578-38-7 tert-butyl N-[6-(hydroxymethyl)pyridin-3-yl]carbamate 
• 1366660-71-0 5-(3-{4-amino-6-[methyl(phenyl)amino]-1,3,5-triazin-2-yl}-1,2,4-oxadiazol-5-yl)-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide 
• 1366660-82-3 2-N-methyl-2-N-phenyl-6-(5-{6-[(2,2,2-trifluoroethoxy)methyl]pyridin-3-yl}-1,2,4-oxadiazol-3-yl)-1,3,5-triazine-2,4-diamine 
• 1366660-84-5 2-N-methyl-2-N-phenyl-6-{5-[6-(pyrrolidin-1-ylmethyl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl}-1,3,5-triazine-2,4-diamine 

Relevant academic research and scientific papers

Anionic guest-dependent slow magnetic relaxation in Co(ii) tripodal iminopyridine complexes

We report the syntheses and magnetic property characterizations of four mononuclear cobalt(ii) complex salts featuring a tripodal iminopyridine ligand with external anion receptor groups, [CoL5-ONHtBu]X2 (X = Cl (1), Br (2), I (3) and ClO4 (4)). While all four salts exhibit anion binding through pendant amide moieties, only in the case of 1 is field-induced slow relaxation of magnetisation observed, whereas in the other salts this phenomenon is absent at the limits of our instrumentation. The effect of chloride inducing a seventh Co-N interaction and concomitant structural distortion is hypothesized as the origin of the observed dynamic magnetic properties observed in 1. Ab initio computational studies carried out on a 7-coordinate Co(ii) model species survey the complex interplay of coordination number and trigonal twisting on the sign and magnitude of the axial anisotropy parameter (D), and identify structural features whose distortions can trigger large switches in the sign and magnitude of magnetic anisotropy.

Characterizing the "shell phase" formed from amphiphilic picolinates

The shell phase forms when certain picolinates are subjected to energy input (via sonication or vortexing) while exposed to a water/toluene mixture. A shell, about 600 A thick and containing the picolinate and (very likely) toluene, surround the water droplets that are always produced during the mixing process. Solubility in either phase appears to be deleterious to shell formation. The shells, stable for months, are not easily distorted but can be punctured, even skewered, with a syringe needle without destroying the sphere, yet there is enough mobility among the molecules to repair the physical damage after the needle is removed. This, plus the absence of evidence for crystallinity, suggests a solid or semisolid film forms when picolinates, with the aid of an aromatic solvent, are provided the energy to rearrange themselves on water droplet surfaces. Structure-activity comparisons among the 10 compounds studied indicate that chain-chain association and intermolecular hydrogen bonding are dominant forces in a side-by-side self-assembly of the molecules within the shells. Copyright

Carboxyl Methyltransferase Catalysed Formation of Mono- and Dimethyl Esters under Aqueous Conditions: Application in Cascade Biocatalysis

Carboxyl methyltransferase (CMT) enzymes catalyse the biomethylation of carboxylic acids under aqueous conditions and have potential for use in synthetic enzyme cascades. Herein we report that the enzyme FtpM from Aspergillus fumigatus can methylate a broad range of aromatic mono- and dicarboxylic acids in good to excellent conversions. The enzyme shows high regioselectivity on its natural substrate fumaryl-l-tyrosine, trans, trans-muconic acid and a number of the dicarboxylic acids tested. Dicarboxylic acids are generally better substrates than monocarboxylic acids, although some substituents are able to compensate for the absence of a second acid group. For dicarboxylic acids, the second methylation shows strong pH dependency with an optimum at pH 5.5–6. Potential for application in industrial biotechnology was demonstrated in a cascade for the production of a bioplastics precursor (FDME) from bioderived 5-hydroxymethylfurfural (HMF).

Enantioselective Rhodium-Catalyzed Dimerization of ω-Allenyl Carboxylic Acids: Straightforward Synthesis of C2-Symmetric Macrodiolides

Herein, we report on the first enantioselective and atom-efficient catalytic one-step dimerization method to selectively transform ω-allenyl carboxylic acids into C2-symmetric 14- to 28-membered bismacrolactones (macrodiolides). This convenient asymmetric access serves as an attractive route towards multiple naturally occuring homodimeric macrocyclic scaffolds and demonstrates excellent efficiency to construct the complex, symmetric core structures. By utilizing a rhodium catalyst with a modified chiral cyclopentylidene-diop ligand, the desired diolides were obtained in good to high yields, high diastereoselectivity, and excellent enantioselectivity.

COMPOUNDS AND METHODS FOR CONJUGATION OF BIOMOLECULES

Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.

NOVEL BEXAROTENE ANALOGS

The present invention relates to analogs of bexarotene and methods of use thereof.

Metallo-controlled dynamic molecular tweezers: Design, synthesis, and self-assembly by metal-ion coordination

The introduction of controllable dynamic features into synthetic receptors represents a step towards "smart" adaptive nanodevices. We report herein our studies on the construction of dynamic molecular tweezers in which the binding of a substrate is allost

CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems ofthe industrialized world In formula I, A-B is an arylamide moiety

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

Oxindole derivatives

The invention describes compounds of the general formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are herein described, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show activity as antiproliferative agents and may be especially useful for the treatment of cancer.